Movers and SHAKERS
|Current Price||$1.13 ↓ -0.02|
|52wk Range||$0.51 - $2.47|
|ADVANCED MARKET DATA|
Advanced Market DataTonix Pharmaceuticals Holding Corp. (TNXP)
509 Madison Avenue
New York, NY 10022
Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company. The company is focused on delivering an efficacious and safe long-term treatment for PTSD. PTSD is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its product candidate, TNX-102 SL, a proprietary low-dose cyclobenzaprine sublingual tablet, designed for bedtime administration, is in Phase 3 development as a potential treatment for PTSD.
If you're not a millionaire now but would like to become one, there's a well-worn path to get there. Just buy pieces of small businesses that become much larger.
Aspiring millionaires have been drawn to Tonix Pharmaceuticals (NASDAQ: TNXP) , a small clinical-stage biotech with some potential new drugs in development that could be worth billions.
Can this company's potential new treatments for fibromyalgia and COVID-19 make millionaires out of bold new investors? To answer this burning question, let's start with this clinical-stage company's lead candidate.
For further details see:Could Tonix Pharmaceuticals Be a Millionaire-Maker Stock?
Tonix Pharmaceuticals Holding Corp. Corporate Filings
Tonix Pharmaceuticals Holding Corp. Corporate Events
Tonix Pharmaceuticals Holding Corp. Press Releases / News Feed
No reports available